Why the study?
COVID-19 can cause extrapulmonary damage including heart injury, requiring clarification of how echocardiography can discriminate primary cardiac disease from COVID-19-related myocardial damage and monitor cardiovascular complications.
Does transthoracic echocardiography help in the diagnostic and therapeutic management of myocardial damage in COVID-19 patients?
Does transthoracic echocardiography help in the diagnostic and therapeutic management of myocardial damage in COVID-19 patients?
Transthoracic echocardiography is a useful tool for discriminating primary cardiac disease from COVID-19-related myocardial damage and monitoring cardiovascular complications in infected patients.
Answers are grounded in this paper and cite their sources.
Echocardiography may aid detection of cardiac involvement in COVID-19; leaves open standardization of protocols and prognostic value.
Coronavirus disease 2019 (COVID-19) outbreak is a current global healthcare burden, leading to the life-threatening severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, evidence showed that, even if the prevalence of COVID-19 damage consists in pulmonary lesions and symptoms, it could also affect other organs, such as heart, liver, and spleen. Particularly, some infected patients refer to the emergency department for cardiovascular symptoms, and around 10% of COVID-19 victims had finally developed heart injury. Therefore, the use of echocardiography, according to the safety local protocols and ensuring the use of personal protective equipment, could be useful firstly to discriminate between primary cardiac disease or COVID-19-related myocardial damage, and then for assessing and monitoring COVID-19 cardiovascular complications: acute myocarditis and arrhythmias, acute heart failure, sepsis-induced myocardial impairment, and right ventricular failure derived from treatment with high-pressure mechanical ventilation. The present review aims to enlighten the applications of transthoracic echocardiography for the diagnostic and therapeutic management of myocardial damage in COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
Cameli et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: